D. Boral Capital Reaffirms Buy Rating for OS Therapies (NYSE:OSTX)

D. Boral Capital restated their buy rating on shares of OS Therapies (NYSE:OSTX) in a research note published on Monday,Benzinga reports. The brokerage currently has a $20.00 price target on the stock.

Separately, Maxim Group lifted their price target on shares of OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, January 16th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, OS Therapies presently has an average rating of “Buy” and a consensus price target of $18.00.

OS Therapies Price Performance

Shares of OSTX stock opened at $1.51 on Monday. OS Therapies has a 52-week low of $1.33 and a 52-week high of $7.00. The company’s 50 day moving average is $1.82 and its 200 day moving average is $2.71.

Insider Transactions at OS Therapies

In other news, major shareholder Shalom Auerbach sold 100,000 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $2.84, for a total value of $284,000.00. Following the sale, the insider now owns 2,431,211 shares in the company, valued at $6,904,639.24. This represents a 3.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 13.80% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in OS Therapies stock. CM Management LLC grew its holdings in OS Therapies Inc (NYSE:OSTX) by 120.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 110,044 shares of the company’s stock after buying an additional 60,044 shares during the quarter. CM Management LLC owned 0.51% of OS Therapies worth $471,000 as of its most recent SEC filing.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.